{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:37:34Z","timestamp":1781890654909,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14908-0","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:22:33Z","timestamp":1759314153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combined anti-tumor effects of metformin and azacitidine in breast cancer cells"],"prefix":"10.1186","volume":"25","author":[{"given":"Setayesh Sadat","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-1144","authenticated-orcid":false,"given":"Nahid","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Yaghoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"5","key":"14908_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"3","key":"14908_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"14908_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.36346\/sarjms.2022.v04i04.001","volume":"4","author":"HS Jasim","year":"2022","unstructured":"Jasim HS. The role of epigenetic drugs in cancer therapy. South Asian Res J Med Sci. 2022;4(4):54\u201362.","journal-title":"South Asian Res J Med Sci"},{"key":"14908_CR4","doi-asserted-by":"crossref","unstructured":"Dakal TC, Dhakar R, Beura A, Moar K, Maurya PK, Sharma NK, et al. Emerging methods and techniques for cancer biomarker discovery. Pathol-Res Pract. 2024;262:155567.","DOI":"10.1016\/j.prp.2024.155567"},{"issue":"1","key":"14908_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/s24010037","volume":"24","author":"S Das","year":"2023","unstructured":"Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors. 2023;24(1):37.","journal-title":"Sensors"},{"issue":"42","key":"14908_CR6","doi-asserted-by":"publisher","first-page":"68803","DOI":"10.18632\/oncotarget.11931","volume":"7","author":"A Amaro","year":"2016","unstructured":"Amaro A, Angelini G, Mirisola V, Esposito AI, Reverberi D, Matis S, et al. A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo. Oncotarget. 2016;7(42):68803.","journal-title":"Oncotarget"},{"issue":"2","key":"14908_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers16020461","volume":"16","author":"B Victoir","year":"2024","unstructured":"Victoir B, Croix C, Gouilleux F, Pri\u00e9 G. Targeted therapeutic strategies for the treatment of cancer. Cancers (Basel). 2024;16(2):461.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"14908_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","volume":"11","author":"SR Bohl","year":"2018","unstructured":"Bohl SR, Bullinger L, R\u00fccker FG. Epigenetic therapy: Azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"14908_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","volume":"89","author":"RE Nicoletto","year":"2022","unstructured":"Nicoletto RE, Ofner CM III. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022;89(3):285\u2013311.","journal-title":"Cancer Chemother Pharmacol"},{"key":"14908_CR10","first-page":"1488","volume":"20","author":"E Zarei","year":"2021","unstructured":"Zarei E, Sefidi-Heris Y, Saadat I. Synergistic effects of Metformin and Curcumin on cytotoxicity of chemotherapy drugs using a gastric cancer cell line model. EXCLI J. 2021;20:1488.","journal-title":"EXCLI J"},{"key":"14908_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00695","volume":"10","author":"J-L Deng","year":"2019","unstructured":"Deng J-L, Xu Y-h, Wang G. Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. Front Genet. 2019;10:695.","journal-title":"Front Genet"},{"issue":"D1","key":"14908_CR12","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","volume":"44","author":"D Szklarczyk","year":"2016","unstructured":"Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"14908_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot. com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622.","journal-title":"Int J Mol Sci"},{"issue":"W1","key":"14908_CR14","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357\u201364.","journal-title":"Nucleic Acids Res"},{"key":"14908_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s10593-014-1496-1","volume":"50","author":"D Filimonov","year":"2014","unstructured":"Filimonov D, Lagunin A, Gloriozova T, Rudik A, Druzhilovskii D, Pogodin P, et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd. 2014;50:444\u201357.","journal-title":"Chem Heterocycl Compd"},{"issue":"35","key":"14908_CR16","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK. 5-azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483\u201395.","journal-title":"Oncogene"},{"key":"14908_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117717","volume":"254","author":"B Zhao","year":"2020","unstructured":"Zhao B, Luo J, Yu T, Zhou L, Lv H, Shang P. Anticancer mechanisms of metformin: a review of the current evidence. Life Sci. 2020;254:117717.","journal-title":"Life Sci"},{"issue":"6","key":"14908_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/10408440500246777","volume":"35","author":"LM Anderson","year":"2005","unstructured":"Anderson LM. Cancer biology and hormesis: comments on calabrese (2005). Crit Rev Toxicol. 2005;35(6):583\u20136.","journal-title":"Crit Rev Toxicol"},{"issue":"1suppl","key":"14908_CR19","first-page":"gahmj","volume":"2","author":"F Smith","year":"2013","unstructured":"Smith F. 24A. Hormesis and integrative medicine. Global Adv Health Med. 2013;2(1suppl):gahmj. 2013.097 CP. S24A.","journal-title":"Global Adv Health Med"},{"issue":"7","key":"14908_CR20","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/cancers14071630","volume":"14","author":"F Tonon","year":"2022","unstructured":"Tonon F, Cemazar M, Kamensek U, Zennaro C, Pozzato G, Caserta S, et al. 5-azacytidine downregulates the proliferation and migration of hepatocellular carcinoma cells in vitro and in vivo by targeting miR-139-5p\/ROCK2 pathway. Cancers (Basel). 2022;14(7):1630.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"14908_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00210-018-01597-9","volume":"392","author":"EK Stuermer","year":"2019","unstructured":"Stuermer EK, Besser M, Terberger N, Koester V, Bachmann HS, Severing AL. Side effects of frequently used oral antidiabetics on wound healing in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(3):371\u201380.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"14908_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lfs.2017.07.029","volume":"185","author":"S Ikhlas","year":"2017","unstructured":"Ikhlas S, Ahmad M. Metformin. Insights into its anticancer potential with special reference to AMPK dependent and independent pathways. Life Sci. 2017;185:53\u201362.","journal-title":"Life Sci"},{"key":"14908_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5667-4","volume":"19","author":"AC Rutkovsky","year":"2019","unstructured":"Rutkovsky AC, Yeh ES, Guest ST, Findlay VJ, Muise-Helmericks RC, Armeson K, et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer. 2019;19:1\u201315.","journal-title":"BMC Cancer"},{"key":"14908_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1076855","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, An Y, Tan M, Xie D, Liu L, Xu B. Biological functions and research progress of eIF4E. Front Oncol. 2023;13:1076855.","journal-title":"Front Oncol"},{"issue":"2","key":"14908_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.21873\/cgp.20315","volume":"19","author":"MD MERKEROVA","year":"2022","unstructured":"MERKEROVA MD, KLEMA J, KUNDRAT D, SZIKSZAI K, KREJCIK Z, HRUSTINCOVA A, et al. Noncoding RNAs and their response predictive value in Azacitidine-treated patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes. Cancer Genomics - Proteom. 2022;19(2):205\u201328.","journal-title":"Cancer Genomics - Proteom"},{"key":"14908_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939784","volume":"12","author":"Z Cai","year":"2022","unstructured":"Cai Z, Xu H, Bai G, Hu H, Wang D, Li H, et al. ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators. Front Oncol. 2022;12:939784.","journal-title":"Front Oncol"},{"issue":"1","key":"14908_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/0929867328666210628143430","volume":"29","author":"D Goutas","year":"2022","unstructured":"Goutas D, Pergaris A, Giaginis C, Theocharis S. HuR as therapeutic target in cancer: what the future holds. Curr Med Chem. 2022;29(1):56\u201365.","journal-title":"Curr Med Chem"},{"issue":"22","key":"14908_CR28","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","volume":"119","author":"J Aimiuwu","year":"2012","unstructured":"Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012;119(22):5229\u201338.","journal-title":"Blood"},{"key":"14908_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.620641","volume":"10","author":"E Cuy\u00e0s","year":"2021","unstructured":"Cuy\u00e0s E, Verdura S, Martin-Castillo B, Menendez JA. Metformin: targeting the metabolo-epigenetic link in cancer biology. Front Oncol. 2021;10:620641.","journal-title":"Front Oncol"},{"issue":"20","key":"14908_CR30","doi-asserted-by":"publisher","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","volume":"69","author":"M Schaefer","year":"2009","unstructured":"Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009;69(20):8127\u201332.","journal-title":"Cancer Res"},{"issue":"17","key":"14908_CR31","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/cells12172182","volume":"12","author":"D Conza","year":"2023","unstructured":"Conza D, Mirra P, Fiory F, Insabato L, Nicol\u00f2 A, Beguinot F, et al. Metformin: a new inhibitor of the Wnt signaling pathway in cancer. Cells. 2023;12(17):2182.","journal-title":"Cells"},{"issue":"3","key":"14908_CR32","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.18632\/oncotarget.13639","volume":"8","author":"X Yu","year":"2016","unstructured":"Yu X, Mao W, Zhai Y, Tong C, Liu M, Ma L, et al. Anti-tumor activity of metformin: from metabolic and epigenetic perspectives. Oncotarget. 2016;8(3):5619.","journal-title":"Oncotarget"},{"issue":"4","key":"14908_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/dna.2012.1926","volume":"32","author":"J Duo","year":"2013","unstructured":"Duo J, Ma Y, Wang G, Han X, Zhang C. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin A against osteosarcoma cell line. DNA Cell Biol. 2013;32(4):156\u201364.","journal-title":"DNA Cell Biol"},{"key":"14908_CR34","first-page":"2425","volume":"2208","author":"CA Hatulely","year":"2023","unstructured":"Hatulely CA. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review. J Adv Res Med Health Sci ISSN. 2023;2208:2425.","journal-title":"J Adv Res Med Health Sci ISSN"},{"issue":"1","key":"14908_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12929-025-01129-7","volume":"32","author":"Z Gu","year":"2025","unstructured":"Gu Z, Ye F, Luo H, Li X, Gong Y, Mao S, et al. Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. J Biomed Sci. 2025;32(1):36.","journal-title":"J Biomed Sci"},{"issue":"86","key":"14908_CR36","doi-asserted-by":"publisher","first-page":"35687","DOI":"10.18632\/oncotarget.26286","volume":"9","author":"B Martin-Castillo","year":"2018","unstructured":"Martin-Castillo B, Pernas S, Dorca J, \u00c1lvarez I, Mart\u00ednez S, P\u00e9rez-Garcia JM, et al. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget. 2018;9(86):35687.","journal-title":"Oncotarget"},{"issue":"1","key":"14908_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11138-3","volume":"12","author":"HE Barakat","year":"2022","unstructured":"Barakat HE, Hussein RR, Elberry AA, Zaki MA, Ramadan ME. The impact of Metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Sci Rep. 2022;12(1):7656.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14908-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:22:35Z","timestamp":1759314155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14908"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14908-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1487"}}